AKRO:NSD-Akero Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 31.05

Change

-0.01 (-0.03)%

Market Cap

USD 1.08B

Volume

0.23M

Average Target Price

USD 67.00 (+115.78%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akero Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for serious metabolic diseases. Its lead product candidate is AKR-001, which is in Phase IIa clinical trial for the treatment of nonalcoholic steatohepatitis disease.The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was founded in 2017 and is headquartered in South San Francisco, California. Address: 170 Harbor Way, South San Francisco, CA, United States, 94080

Company Website : http://www.akerotx.com

Address : 170 Harbor Way, South San Francisco, CA, United States, 94080

Employees : 16

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

52 Week High : 41.16

Short Ratio : 10.16

52 Week Low : 10.78

Shorted Shares : 2,530,734

200 Day Moving Average : 30.89

Shorted Shares Previous Month : 1,909,897

50 Day Moving Average : 27.47

Shares Held By Insiders : 83.97%

Short Percentage : 7.00%

Shares Held by Institutions : 93.8%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.72 (+1.57%)

 USD61.78B 23.28 18.31
REGN Regeneron Pharmaceuticals, Inc

+10.42 (+1.94%)

 USD57.38B 19.71 15.20
MRNA Moderna, Inc

+15.98 (+12.20%)

 USD51.85B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.59 (+1.00%)

 USD34.94B 37.07 34.58
BGNE BeiGene, Ltd

+2.41 (+0.64%)

 USD34.10B N/A N/A
SGEN Seagen Inc

-2.63 (-1.44%)

 USD32.71B 69.01 69.56
RPRX Royalty Pharma plc

+0.34 (+0.66%)

 USD31.99B 22.60 11.74
GMAB Genmab A/S

-0.36 (-0.84%)

 USD28.33B 26.59 3.19
BNTX BioNTech SE

+2.17 (+2.00%)

 USD26.11B -99,999.99 N/A
INCY Incyte Corporation

+2.61 (+2.67%)

 USD21.44B 47.64 35.20

ETFs Containing AKRO

Symbol Name Weight Mer Price(Change) Market Cap
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

+0.82 (+1.53%)

 USD0.05B
DWMC AdvisorShares Dorsey Wrig.. 0.00 % 1.25 %

+0.02 (+0.05%)

 USD2.90M
PQSG PGIM QMA Strategic Alpha .. 0.00 % 0.29 %

+0.05 (+0.07%)

 USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.35% 60% D- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.35% 60% D- 77% C+
Trailing 12 Months  
Capital Gain 31.62% 52% F 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.62% 52% F 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 16.02% 57% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.02% 57% F 71% C-
Risk Return Profile  
Volatility (Standard Deviation) 24.89% 91% A- 59% F
Risk Adjusted Return 64.35% 89% B+ 81% B-
Market Capitalization 1.08B 71% C- 65% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.18 46% F 78% C+
Price/Book Ratio 3.76 65% D 43% F
Price / Cash Flow Ratio -30.27 81% B- 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -30.29% 79% C+ 30% F
Return on Invested Capital -115.86% 21% F 8% F
Return on Assets -18.49% 70% C- 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 10.16 12% F 7% F
Short Percent 13.29% 21% F 16% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector